Company intelligence / Profile preview

Vaneltix Pharma

New Brunswick, New Jersey, United Statesvaneltix.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Vaneltix's lead product Alenura® is currently in Phase 2 clinical trials. The company started a multiple dose clinical trial (VNX001-110) in December 2024 to study the safety, efficacy, and frequency of administration of VNX001 (Alenura®) in the treatment of IC/BPS[3]. This follows their previous VNX001-111 trial (renamed Engage 2024 study).

Therapeutic areas: Women's HealthNephrology
Modalities: Combination productsbiologicsoral formulationstopical formulations
Industry: Biotech

Drug pipeline

4 assets

VNX001

3 more assets in the full pipeline.

Request access →

Partnerships

Hyloris Pharmaceuticals NV (Joint Development Agreement for Alenura signed December 16, 2021)[6]

Beyond the preview

Go deeper on Vaneltix Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vaneltix Pharma.

Explore the full profile